1 – 10 of 89
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma
(
- Contribution to journal › Article
-
Mark
European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022 : The Urologist's Point of View
(
- Contribution to journal › Debate/Note/Editorial
- 2022
-
Mark
Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
(
- Contribution to journal › Article
-
Mark
European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)
(
- Contribution to journal › Scientific review
-
Mark
Re: Keisuke Shigeta, Kazuhiro Matsumoto, Koichiro Ogihara, et al. Does Neoadjuvant Chemotherapy Have Therapeutic Benefit for Node-positive Upper Tract Urothelial Carcinoma? Results of a Multi-center Cohort Study. Urol Oncol. In press. https://doi.org/10.1016/j.urolonc.2021.07.029 : A Plea for Uniform Terminology for Patients with Urothelial Carcinoma Treated with Chemotherapy Before Consolidative Surgery with Curative Intent: Induction Versus Neoadjuvant Chemotherapy
(
- Contribution to journal › Letter
-
Mark
Reply to Wei Zhang So, Ziting Wang, and Ho Yee Tiong's Letter to the Editor re : Anna Lantz, David Bock, Olof Akre, et al. Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up. Eur Urol 2021;80:650–60
(
- Contribution to journal › Letter
-
Mark
Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
(
- Contribution to journal › Letter
-
Mark
2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma
(
- Contribution to journal › Article
-
Mark
Smoking and Risk of Prostate Cancer and Prostate Cancer Death : A Pooled Study
2022) In European Urology(
- Contribution to journal › Article
-
Mark
European Association of Urology Guidelines on Renal Cell Carcinoma : The 2022 Update
(
- Contribution to journal › Scientific review